Why the study?
Does testing for troponin T and I improve the detection of myocardial damage and risk assessment compared to conventional markers in patients with suspected ACS and other clinical situations?
Does testing for troponin T and I improve the detection of myocardial damage and risk assessment compared to conventional markers in patients with suspected ACS and other clinical situations?
Answers are grounded in this paper and cite their sources.
Troponins T and I are superior to conventional biomarkers for detecting myocardial damage, aiding in diagnosis, risk assessment, and treatment selection in ACS and post-procedural settings.
Biochemical markers of myocardial damage are together with the clinical history, the physical examination and the 12-lead ECG key elements in the clinical evaluation of patients presenting with symptoms suggestive of an acute coronary syndrome (ACS). In this situation the detection of myocardial damage, even very minor, is of importance, not only for diagnosis, but also for risk assessment and selection of treatment. The new markers of myocardial damage. troponin T and I, have been shown to offer some advantages over the conventional markers in ACS and there is also an increasing interest for troponins in other clinical situations, e.g. after surgery and percutaneous coronary intervention. This paper will discuss the role of troponins in these different clinical situations.
No takes yet. Share an insight, caveat, or question.
Bertil Lindahl (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: